CA-CIRCLECI
CircleCI, the leading continuous integration and continuous delivery (CI/CD) platform, today unveiled CircleCI releases, which enables developers to automate the release orchestration process directly from the CircleCI UI. With current support for Kubernetes and Amazon SageMaker, developers now have end-to-end visibility of their deployments in production and access to rollback commands (e.g., restore version, scale component, and restart component) for seamless release management. CircleCI releases makes deploying code less risky, user-focused, and more accessible for developers to ship faster with confidence.
Today, developers operate in increasingly complex tech stacks yet are under pressure to move quickly without compromising software quality. As a result, elite engineering teams are incorporating agile development practices like progressive delivery and canary releases, which provide the guardrails necessary for risk-free deployments via the ability to target, segment, and roll back releases. CircleCI releases enables software teams to automate the progressive delivery process with support for Argo Rollouts, giving developers complete control over their releases. Future support for blue-green deployments is slated for later in 2024. By automating CI/CD pipelines directly into the release orchestration process, software teams dramatically reduce mean-time-to-recovery (MTTR), giving them the confidence to resolve issues should releases go awry with little to no impact on their customers.
Key features and benefits of CircleCI releases include:
- Change validation: Developers can validate the entire change from build to production.
- User-focused releases and minimized risk: Developers can connect their CI/CD pipeline directly to the customer experience to make releases user-focused, risk-free, and rollback-friendly.
- Increased code confidence: With automated release orchestration, teams will definitively know that their code is working as intended.
- Automated rollbacks: Manual rollbacks take 45 minutes to an hour. Automated rollbacks make the delivery process fast, efficient, and streamlined.
- Real-time service validation: Developers can safely release code to a controlled subset of real users in a live production environment to get immediate feedback on how code performs. Flexible subsets include internal testers, beta customers, or an external low-risk customer group of choice.
- Performance degradation prevention: Automate your release conditions and best practices into a release policy to act as guardrails. By automating software validation in production and rolling back releases when necessary, developers, operators, and customers are protected from performance degradation.
“If you look at every other deploy and release vendor on the market, they’re built to service centralized release and operations teams who want tighter control over deploys,” said Rob Zuber, CTO of CircleCI. “But this doesn’t reflect the reality of elite software teams who depend on developers to drive and deliver fast innovation. Our approach to CircleCI releases provides a developer-centric workflow that enables them to ship faster and monitor new features in production coupled with the safety net of quickly rolling back releases if something goes wrong.”
CircleCI releases is now available to all CircleCI users. To learn more or chat about how CircleCI can empower your team to deliver innovation faster, visit one of our experts at KubeCon EU, booth M16 from March 19-21, 2024. Get started using CircleCI releases today.
About CircleCI
CircleCI is a leading continuous integration and continuous delivery (CI/CD) platform, enabling more than two million global users on elite engineering teams like Okta, Hinge, and Hugging Face to rapidly build, test, deploy, and monitor software they can trust. Through powerful pipeline automation, CircleCI manages limitless complexity at scale through unmatched flexibility and reliability, reducing the time from build to delivery by 3x the industry average. For more information about CircleCI, visit www.circleci.com or follow us on Twitter, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314509917/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zayed Sustainability Prize Opens Global Call for Submissions for 2027 Cycle26.1.2026 16:25:00 CET | Press release
With an increased prize fund of US $7.2 million, the Zayed Sustainability Prize supports enterprises, nonprofit organisations and schools delivering transformative solutions.Entries are now open, with applicants invited to submit innovative, scalable sustainability solutions.Now in its 18th year, the Prize has positively impacted over 400 million people by expanding access to clean energy, water, food, healthcare and improving climate resilience. The Zayed Sustainability Prize, an affiliate of Erth Zayed Philanthropies and the UAE’s pioneering global award for sustainability and humanitarian innovation, has opened submissions for its 2027 cycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126912976/en/ Winners of the 2026 Zayed Sustainability Prize (Photo: AETOSWire) The Prize carries forward the vision and legacy of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, by supporting those advancing a more incl
2026 Japan Prize: Two U.S. Scientists and One Japanese Scientist Awarded26.1.2026 15:00:00 CET | Press release
Presentation Ceremony to Take Place in Tokyo in April The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication
Uzbekistan, the Engine of Central Asia: GDP Above USD 145 Billion and Exports Rising to USD 33.4 Billion – Embassy of the Republic of Uzbekistan in Italy26.1.2026 14:31:00 CET | Press release
With a GDP exceeding USD 145 billion, exports of USD 33.4 billion up 23 percent, and gold reserves surpassing USD 60 billion, Uzbekistan enters 2026 with solid and steadily strengthening macroeconomic indicators. The Embassy of the Republic of Uzbekistan in Italy claims that the climate of confidence, reaffirmed in the State of the Nation Address delivered on 26 December by President Shavkat Mirziyoyev, is reflected in international trade data: total foreign investment has reached USD 43.1 billion, equal to 31.9 percent of GDP. This trajectory has also contributed to an improvement in the country’s sovereign rating, upgraded to BB by the leading international rating agencies. For the current year, the Government forecasts economic growth of 6.6 percent, with GDP estimated at USD 167 billion. A total of 782 new industrial and infrastructure projects will be launched, with an overall value of USD 52 billion, including 228 large production facilities as early as next year. The focus will
Lucend, Formerly Coolgradient, Raises $3.3M to Bring Transparent AI to Data Centers to Increase Uptime and Reliability While Maximizing Efficiency26.1.2026 14:00:00 CET | Press release
Lucend Seed round led by Remarkable Ventures Climate (RVC) to bring Transparent AI insights to data center operators in the U.S. increasing operational efficiency by 40% Lucend today announced that it is bringing its transparent data center optimization to the U.S. market, helping enterprises illuminate complex operational environments and empowering data center operators, innovation officers, and sustainability officers with the intelligence they need to act with trust, accuracy, and confidence. Lucend’s Transparent AI platform connects to existing infrastructure, no new hardware required, to transform static systems into adaptive, self-learning environments. The software takes existing sensor data to see connections across 300 billion sensor readings. Lucend’s AI analyzes billions of data points daily and provides prescriptive recommendations. The intelligence that Lucend’s platform delivers “shows its work,” empowering operators and delivering verifiable impact across enterprise env
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis26.1.2026 14:00:00 CET | Press release
Study could lead to first-ever topical steroid-free treatment for the inner eye disease non-infectious anterior uveitis (NIAU) The study builds on ocular pharmacokinetic models demonstrating delivery after topical application and on animal models of experimental uveitis demonstrating pharmacological effects Novaliq is expanding with this proof-of-concept study into retina and inner-eye diseases as targeted topical delivery of EyeSol®-based drugs allowing to develop breakthrough therapies Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases. NOV05, tacrolimus ophthalmic solution in EyeSol®, is a unique, steroid-free topical anti-inflammatory treatment. The IND clearance enables initiation of the EYETAC Pha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom